Exelixis Stock Falls After FDA Delays Approval of New Colon Cancer Treatment
Exelixis (EXEL) stock declined on Friday following an unexpected three-month delay in the potential approval of its new colon cancer treatment by the U.S. Food and Drug Administration. The drug combination includes Exelixis' zanzalintinib paired with Roche's Tecentriq, which demonstrated overall survival benefits for patients during trials. William Blair analyst Andy Hsieh noted that while a full rejection of the therapy is unlikely, the delay has caused uncertainty in investor sentiment and pulled EXEL stock out of its buy zone. The setback highlights regulatory risks associated with drug development timelines and their impact on market confidence.
Topics: clinical trials drug development stock price movement